ASCO 2018 - QIAGEN CEO Peer Schatz about the development of precision diagnostics in oncology

Interview with Peer Schatz, CEO of QIAGEN, about the importance of the ASCO annual meeting and how working with pharmaceutical companies furthers the development of precision diagnostics in oncology. QIAGEN utilizes NGS to provide new opportunities for the development of cancer treatments, and is working with partners in all areas to bring patients the best possible molecular diagnostics to guide personalized treatments.